Coherus Oncology, Inc. (CHRS)

Several events have impacted Coherus Oncology's stock price in the past six months. LOQTORZI received approval in Canada in October 2025. The Q3 2025 financial results, reported on November 6, 2025, showed LOQTORZI net revenue of $11.2 million. On February 12, 2026, Coherus Oncology announced the pricing of a public offering of 28,600,000 shares at $1.75 per share. The company reported its full-year and Q4 2025 results on March 9, 2026, with LOQTORZI revenue more than doubling and a significant reduction in debt. In March 2026, Coherus Oncology's stock rating was upgraded to a Zacks Rank #2 (Buy). The company's share price has experienced volatility over the past three months compared to the U.S. market.

Information regarding specific demand seasonality for Coherus Oncology, Inc.'s products and services is not publicly detailed. Given that Coherus Oncology focuses on cancer immunotherapies, significant seasonality in demand for its products is generally less likely compared to consumer goods or elective procedures. Demand for oncology treatments is typically driven by disease incidence and progression rather than seasonal factors.

Coherus Oncology, Inc. (CHRS) is a commercial-stage innovative oncology company focused on researching, developing, and commercializing immunotherapies to treat cancer, operating within the Healthcare sector, specifically in the Biotechnology industry. Headquartered in California's Silicon Valley, Coherus Oncology transitioned from a biosimilars company to an oncology-focused entity in May 2025. The company's major products include LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor approved in the United States for recurrent or metastatic nasopharyngeal carcinoma (NPC), Tagmokitug (CHS-114), a highly selective cytolytic anti-CCR8 antibody in Phase 1b/2a studies, Casdozokitug, a novel IL-27 antagonistic antibody in a Phase 2 study, and UDENYCA® (pegfilgrastim-cbqv), which was divested in April 2025.

Coherus Oncology, Inc. is headquartered in Redwood City, California, United States, and primarily commercializes its products in the United States. In October 2025, LOQTORZI also received approval in Canada, expanding its market presence.

Coherus Oncology's brand reputation has been shaped by its strategic transformation and commercial progress. The company rebranded to Coherus Oncology in May 2025 to focus on cancer immunotherapy treatments. Positive events include strong LOQTORZI sales growth, significant debt reduction, pipeline progress, and FDA approval of LOQTORZI. No specific negative events or controversies significantly impacting Coherus Oncology's brand reputation in the past year were found.

Coherus Oncology, Inc. has significant institutional ownership, with 136 institutional owners holding 51,299,972 shares as of March 27, 2026. Institutional shareholders own 34.23% of the stock, while insiders own 14.29%, and retail investors hold 51.48%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Kohlberg Kravis Roberts & Co. L.P. A significant individual/entity owner is V-Sciences Investments Pte Ltd, which directly owns 7,381,116 shares, representing 4.92% of the company. Other notable insider owners include Dennis M. Lanfear (CEO), Lilly Co Eli, Daiichi Sankyo Company Ltd, and Kkr Biosimilar LP.